Abstract
Since recent research has suggested that the major metabolites of progesterone are barbiturate-like modulators of GABAergic function, we undertook a pilot study of the efficacy of micronized progesterone in attenuating withdrawal and facilitating discontinuation in benzodiazepine-dependent patients with a minimum of 1 year of continuous daily use. Forty-three patients taking a mean daily dose of 16.2 mg of diazepam (or its equivalent) were assigned, double-blind, to treatment with either placebo (n=13) or progesterone (n=30). Progesterone was titrated to a mean daily dose of 1983 mg, and was co-administered for 3 weeks, after which the benzodiazepine was tapered by 25% per week. Progesterone (or placebo) was then continued for 4 weeks before being discontinued. There was no progesterone versus placebo difference in the severity of taper withdrawal. Withdrawal checklist change scores were 17.3 for progesterone and 16.5 for placebo (F 0.63;df 2,31; n.s.), and the Hamilton rating scale for anxiety change scores were 7.8 for progesterone and 6.3 for placebo (F 0.22;df 2,30; n.s.). There was no difference in ability to remain drug-free at 12 weeks post-taper, with 57% of progesterone-treated patients, and 58% of placebo-treated patients having a successful outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Psychiatric Association (1990) Benzodiazepine dependence, toxicity, and abuse: a task force report of the American Psychiatric Association, APA, Washington
Ansseau M, De Roeck J (1993) Trazodone in benzodiazepine dependence. J Clin Psychiatry 54: 189–191
Arafat ES, Hargrove JT, Maxson WS, Desiderio DM, Wentz AC, Anderson RN (1988) Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. Am J Obstet Gynecol 159: 1203–1209
Auta J, Romeo E, Kozikowski A, Ma D, Costa E, Guidotti A (1993) Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl-3-indoleacetamide and imidazopyridine derivatives. J Pharmacol Exp Ther 265[2]: 649–656
Backstrom T, Landgrent S, Zetterland B (1984) Effects of ovarian steroid hormones on brain excitability and their relation to epilepsy seizure variation during the menstrual cycle. In: Porter RJ et al. (eds) Advances in epileptology: XVth Epilepsy International Symposium. Raven, New York, pp 269–277
Bitran D, Purdy RH, Kellogg CK (1993) Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacol Biochem Behav 45[2]: 423–428
Covi L, Lipman RS, Pattison JH, Derogatis LR, Uhlenhuth EH (1973) Length of treatment with anxiolytic sedatives and response to their sudden withdrawal. Acta Psychiatr Scand 49: 51–64
Crawley JN, Glowa JR, Majewska MD, Paul SM (1986) Anxiolytic activity of an endogenous adrenal steroid. Brain Res 398[2]: 382–385
Freeman EW, Weinstock L, Rickels K, Sondheimer S, Coutifaris C (1992) A placebo-controlled study of effects of oral progesterone on performance and mood. Br J Clin Pharmacol 33: 293–298
Freeman EW, Purdy RH, Coutifaris C, Rickels K, Paul SM (1993) Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 58: 478–484
Gee KW, Brinton RE, Chang WC, McEwen BS (1987) Gamma aminobutyric acid-dependent modulation of the chloride ionophore by steroids in rat brain. Eur J Pharmacol 136: 419–423
Goodman WK, Charney DS, Price LH, Woods SW, Heninger GR (1986) Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry 143: 900–903
Greenblatt DJ, Franke K, Shader RI (1978) Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography: use in pharmacokinetic studies of lorazepam. J Chromatogr 146: 311–320
Greenblatt DJ, Ochs HR, Lloyd BL (1980) Entry of diazepam and its major metabolite into cerebrospinal fluid. Psychopharmacology 70: 89–93
Greenblatt DJ, Divoll M, Shader RI (1983) Automated gas chromatographic determination of plasma alprazolam concentrations. J Clin Psychopharmacol 3: 366–368
Keck PE, McElroy SL, Friedman LM (1992) Valproate and carbamazepine in the treatment of panic and post-traumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 12[1 Suppl]: 36S-41S
Lader M, Olajide D (1987) A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacol 7: 11–15
Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232: 1004–1007
Mendelson WB, Martin JV, Perlis M, Wagner R, Majewska MD, Paul JM (1987) Sleep induction by an adrenal steroid in the rat. Psychopharmacology 93: 226–229
Miller LG, Greenblatt DJ, Lopez F, Schatzki A, Heller J, Lumpkin M, Shader RI (1990) Chronic benzodiazepine administration: effects in vivo and in vitro. Adv Biochem Psychopharmacol 46: 167–175
Morrow AL, Suzdak PD, Paul SM (1987) Steroid hormone metabolites potentiate GABA receptor-mediated chloride ion flux with nanomolar potency. Eur J Pharmacol 142: 483–485
Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF (1993) Discotinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 150[10]: 1485–1490
Ottoson U-B, Carlstrom K, Damber J-E, Von Schoultz B (1984) Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral parenteral administration. Br J Obstet Gynecol 91: 1111–1119
Rickels K, Schweizer E, Case WG, Greenblatt DJ (1990) Long-term therapeutic use of benzodiazepines. I. effects of abrupt discontinuation. Arch Gen Psychiatry 47: 899–907
Rickels K, Case WG, Schweizer E (1991) Management of benzodiazepine discontinuation. Biol Psychiatry I: 778–779. [Proceedings of 5th World Congress of Biological Psychiatry, Florence, Italy, 6/9–14/91]
SAS (1987) SAS 6.03: statistical analysis systems, SAS Institute, Cary, N.C.
Schweizer E, Rickels K (1986) Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 143: 1590–1592
Schweizer E, Rickels K, Case WG, Greenblatt DJ (1991) Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry 48: 448–452
Smith DE, Wesson DR (1985) Benzodiazepine dependency syndromes. In: Smith DE, Wesson DR (eds) The benzodiazepines: current standards for medical practice. MTP, Hingham, Massachusetts Lancaster, England, pp 235–248
Tyrer P, Rutherford D, Huggett T (1981) Benzodiazepine withdrawal symptoms and propranolol. Lancet 1: 520–522
Wieland S, Lan NC, Mirasedeghi S, Gee KW (1991) Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3-alpha-o1-20-one. Brain Res 565[2]: 263–268
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schweizer, E., Case, W.G., Garcia-Espana, F. et al. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology 117, 424–429 (1995). https://doi.org/10.1007/BF02246214
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246214